Claims
- 1. A method for the treatment of a patient infected with a hepatitis C virus, comprising administering gemcitabine or its pharmaceutically acceptable salt or prodrug
(i) in an amount between 50-1300 mg/M2 of host surface area (ii) in a dosage regimen of daily for one, two, three., four, five, six or seven consecutive days followed by cessation of therapy.
- 2. The method of claim 1 wherein gemcitabine or its salt or prodrug is administered in an amount between 200-1000 mg/M2 per day.
- 3. The method of claim 1 wherein gemcitabine is administered in an amount between 300-800 mg/m2 per day.
- 4. The method of claim 1 wherein the dosage regimen is once a day for one day.
- 5. The method of claim 1 wherein the dosage regimen is once a day for two days.
- 6. The method of claim 1 wherein the dosage regimen is once a day for three days.
- 7. The method of claim 1 wherein the dosage regimen is once a day for four days.
- 8. The method of claim 1 wherein the dosage regimen is once a day for five days.
- 9. The method of claim 1 wherein the dosage regimen is once a day for six days.
- 10. The method of claim 1 wherein the dosage regimen is once a day for seven days.
- 11. The method of claim 1 wherein the dosage is administered intravenously.
- 12. The method of claim 1, wherein the therapy is ceased for at least two days.
- 13. The method of claim 1, wherein the therapy is ceased for at least three days.
- 14. The method of claim 1, wherein the therapy is ceased for at least one week.
- 15. The method of claim 1, wherein the therapy is ceased for at least two weeks.
- 16. The method of claim 1, wherein the therapy is ceased for at least three weeks.
- 17. The method of claim 1, wherein the therapy is ceased for at least one month.
- 18. A method for the treatment of a patient infected with a Flaviviridae infection, comprising administering gemcitabine or its pharmaceutically acceptable salt or prodrug (iii) in an amount between 50-1300 mg/M2 of host surface area (iv) in a dosage regimen of daily for one, two, three., four, five, six or seven consecutive days followed by cessation of therapy.
- 19. The method of claim 18 wherein gemcitabine or its salt or prodrug is administered in an amount between 200-1000 mg/m2 per day.
- 20. The method of claim 18 wherein gemcitabine is administered in an amount between 300-800 mg/m2 per day.
- 21. The method of claim 18 wherein the dosage regimen is once a day for one day.
- 22. The method of claim 18 wherein the dosage regimen is once a day for two days.
- 23. The method of claim 18 wherein the dosage regimen is once a day for three days.
- 24. The method of claim 18 wherein the dosage regimen is once a day for four days.
- 25. The method of claim 18 wherein the dosage regimen is once a day for five days.
- 26. The method of claim 18 wherein the dosage regimen is once a day for six days.
- 27. The method of claim 18 wherein the dosage regimen is once a day for seven days.
- 28. The method of claim 18 wherein the dosage is administered intravenously.
- 29. The method of claim 18 wherein the therapy is ceased for at least two days.
- 30. The method of claim 18, wherein the therapy is ceased for at least three days.
- 31. The method of claim 18, wherein the therapy is ceased for at least one week.
- 32. The method of claim 18, wherein the therapy is ceased for at least two weeks.
- 33. The method of claim 18, wherein the therapy is ceased for at least three weeks.
- 34. The method of claim 18, wherein the therapy is ceased for at least one month.
- 35. A method for the treatment of Flaviviridae virus, comprising administering an antivirally effective amount of a β-D or β-L nucleoside of the structure:
- 36. The method of claim 35 wherein X is NH2, Z is O, R3 is OH, and R is H.
- 37. The method of claim 35 wherein gemcitabine or its salt or prodrug is administered in an amount between 200-1000 mg/M2 per day.
- 38. The method of claim 35 wherein gemcitabine is administered in an amount between 300-800 mg/m2 per day.
- 39. The method of claim 35 wherein the dosage regimen is once a day for one day.
- 40. The method of claim 35 wherein the dosage regimen is once a day for two days.
- 41. The method of claim 35 wherein the dosage regimen is once a day for three days.
- 42. The method of claim 35 wherein the dosage regimen is once a day for four days.
- 43. The method of claim 35 wherein the dosage regimen is once a day for five days.
- 44. The method of claim 35 wherein the dosage regimen is once a day for six days.
- 45. The method of claim 35 wherein the dosage regimen is once a day for seven days.
- 46. The method of claim 35 wherein the dosage is administered intravenously.
- 47. The method of claim 35, wherein the therapy is ceased for at least two days.
- 48. The method of claim 35, wherein the therapy is ceased for at least three days.
- 49. The method of claim 35, wherein the therapy is ceased for at least one week.
- 50. The method of claim 35, wherein the therapy is ceased for at least two weeks.
- 51. The method of claim 35, wherein the therapy is ceased for at least three weeks.
- 52. The method of claim 35, wherein the therapy is ceased for at least one month.
- 53. The method of claim 35, wherein the Flaviviridae is hepatitis C virus.
- 54. The method of claim 18 or 35, wherein the Flaviviridae is West Nile Virus.
- 55. The method of claim 18 or 35, wherein the Flaviviridae is Dengue virus.
- 56. The method of claim 18 or 35, wherein the Flaviviridae is Bovine Viral Diarrhea Virus.
- 57. The method of claim 18 or 35, wherein the Flaviviridae is Border Disease Virus.
- 58. The method of claim 18 or 35, wherein the Flaviviridae is Yellow Fever virus.
Parent Case Info
[0001] This application claims priority to U.S. patent application No. 60/357,411, filed on Feb. 14, 2002, and U.S. patent application No. 60/358,140, filed on Feb. 20, 2002.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60357411 |
Feb 2002 |
US |
|
60358140 |
Feb 2002 |
US |